Independent predictors of morbidity after image-guided stereotactic brain biopsy: a risk assessment of 270 cases
- 1 May 2005
- journal article
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery
- Vol. 102 (5), 897-901
- https://doi.org/10.3171/jns.2005.102.5.0897
Abstract
Image-guided stereotactic brain biopsy is associated with transient and permanent incidences of morbidity in 9 and 4.5% of patients, respectively. The goal of this study was to perform a critical analysis of risk factors predictive of an enhanced operative risk in frame-based and frameless stereotactic brain biopsy. The authors reviewed the clinical and neuroimaging records of 270 patients who underwent consecutive frame-based and frameless image-guided stereotactic brain biopsies. The association between preoperative variables and biopsy-related morbidity was assessed by performing a multivariate logistic regression analysis. Transient and permanent stereotactic biopsy-related morbidity was observed in 23 (9%) and 13 (5%) patients, respectively. A hematoma occurred at the biopsy site in 25 patients (9%); 10 patients (4%) were symptomatic. Diabetes mellitus (odds ratio [OR] 3.73, 95% confidence interval [CI] 1.37-10.17, p = 0.01), thalamic lesions (OR 4.06, 95% CI 1.63-10.11, p = 0.002), and basal ganglia lesions (OR 3.29, 95% CI 1.05-10.25, p = 0.04) were in'dependent risk factors for morbidity. In diabetic patients, a serum level of glucose that was greater than 200 mg/dl on the day of biopsy had a 100% positive predictive value and a glucose level lower than 200 mg/dl on the same day had a 95% negative predictive value for biopsy-related morbidity. Pontine biopsy was not a risk factor for morbidity. Only two (4%) of 45 patients who had epilepsy before the biopsy experienced seizures postoperatively. The creation of more than one needle trajectory increased the incidence of neurological deficits from 17 to 44% when associated with the treatment of deep lesions (those in the basal ganglia or thalamus; p = 0.05), but was not associated with morbidity when associated with the treatment of cortex lesions. Basal ganglia lesions, thalamic lesions, and patients with diabetes were independent risk factors for biopsy-associated morbidity. Hyperglycemia on the day of biopsy predicted morbidity in the diabetic population. Epilepsy did not predispose to biopsy-associated seizure. For deep-seated lesions, increasing the number of biopsy samples along an established track rather than performing a second trajectory may minimize the incidence of morbidity. Close perioperative observation of glucose levels may be warranted.This publication has 25 references indexed in Scilit:
- Frameless Stereotactic Brain Biopsy Procedures Using the Stealth Station: Indications, Accuracy and ResultsCentral European Neurosurgery, 2003
- CT-guided stereotactic biopsies of brain stem lesions: personal experience and literature reviewNeurological Sciences, 2003
- Histological yield, complications, and technological considerations in 114 consecutive frameless stereotactic biopsy procedures aided by open intraoperative magnetic resonance imagingJournal of Neurosurgery, 2002
- Comprehensive assessment of hemorrhage risks and outcomes after stereotactic brain biopsyJournal of Neurosurgery, 2001
- Hyperglycemia Increases Neurological Damage and Behavioral Deficits From Post-Traumatic Secondary Ischeie InsultsJournal of Neurotrauma, 1998
- Diagnostic yield in CT-guided stereotactic biopsy of gliomasJournal of Neurosurgery, 1989
- The Incidence of Unexpected Pathological Findings in an Image-Guided Biopsy Series: A Review of 100 Consecutive CasesNeurosurgery, 1989
- Computed Imaging Stereotaxy: Experience and Perspective Related to 500 Procedures Applied to Brain MassesNeurosurgery, 1987
- Computed Tomographic Guidance Stereotaxis in the Management of Intracranial Mass LesionsNeurosurgery, 1983
- Stereotactic biopsies and computer tomography in gliomasActa Neurochirurgica, 1978